2023 NIAID Omnibus Broad Agency Announcement
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a cost-reimbursement contract to THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC under the 2023 NIAID Omnibus Broad Agency Announcement. The contract, valued at $9,851,406, was awarded on May 9, 2024 under full and open competition to provide goods or services related to research and development in the area of infectious diseases, as the costs could not be adequately defined at the time of contract award.
HHS-NIH-NIAID-BAA2023-1 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
5/9/24, 11:32 AM 2023 NIAID Omnibus Broad Agency Announcement
AMENDMENT ONE
The purpose of Amendment One is to:
Provide the NIAID’s response to questions received regarding the solicitation. The responses are offered for information only and do not modify or become part of this solicitation. Additional amendments may be provided as needed to address further questions and their related responses.
Provide a cut-off date for questions for each Research Area.
_______________________________________________________________________________________________________
Introduction:
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement (BAA) is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH.
The following four (4) distinct Research Areas are included in the attached NIAID DMID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2023-1, which NIAID aims to advance the R&D of promising candidate vaccines, therapeutics, and diagnostics for Biodefense, Emerging Infectious Diseases, and Pandemic Preparedness:
Research Area 001 – Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
The goal of Research Area 001 is to protect human health and well-being by advancing specific vaccine candidates that utilize technology platforms that ideally elicit a rapid onset of immunity following a single dose, provide a durable response and are readily adaptable to multiple emerging pathogens.
Research Area 002 – Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
The objective of Research Area 002 is the development of new therapeutics for diseases caused by NIAID Emerging Infectious Diseases/Pathogens including Category A, B and C priority pathogens and certain bacterial and fungal pathogens identified in the 2019 CDC Antibiotic Resistance Threats Report.
Research Area 003 – Antiviral Program for Pandemics (APP): Development of Antivirals for RNA Viral Families of Pandemic Potential
The Antiviral Program for Pandemics (APP; https://www.niaid.nih.gov/research/antivirals) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Research Area 004 – Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases
NIAID is interested in supporting the development of promising diagnostics technologies in three areas for detection of signatures from biothreat pathogens and toxins, as well as pathogens causing emerging, reemerging, antimicrobial resistant infectious diseases, and for pandemic preparedness.
Next-generation Nucleic Acid Sequencing on Portable Systems
Rapid Protein Detection
Bacterial Identification and Phenotypic Antimicrobial Resistance Characterization.
An offeror should carefully review the content of the BAA for information regarding the technical objective of each Research Area of this omnibus BAA, instructions regarding the proposal submission, and a description of the evaluation and award process; and exercise its professional judgement in compiling its proposal.
Each of the four (4) distinct Research Areas has a specified closing date and time. The proposals due date of March 13, 2023, specified in this solicitation posting, is the due date for Research Area 003 only. An Amendment will be issued at a later date to update the proposal due date for responses to Research Areas 001, 002, and 004. The proposals due date for each Research Area are identified below:
Research Area 001 - Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
Proposals Due Date and Time – April 11, 2023, 3:00PM Eastern Time
Research Area 002 - Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
Proposals Due Date and Time – April 11, 2023, 3:00PM Eastern Time
Research Area 003 - The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential
Proposals Due Date and Time – March 13, 2023, 3:00PM Eastern Time
Research Area 004 - Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases
Proposals Due Date and Time – April 11, 2023, 3:00PM Eastern Time
For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted.
For directions on using eCPS, go to the website: https://ecps.nih.gov and then click on "How to Submit."
HHS-NIH-NIAID-BAA2023-1 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
1/11/23, 1:48 PM